A new trading day began on Tuesday, with Pacific Biosciences of California Inc (NASDAQ: PACB) stock price up 4.74% from the previous day of trading, before settling in for the closing price of $2.32. PACB’s price has ranged from $0.85 to $2.72 over the past 52 weeks.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -23.55%. Meanwhile, its annual earnings per share averaged -64.88%. With a float of $270.83 million, this company’s outstanding shares have now reached $301.85 million.
Considering the fact that the conglomerate employs 575 people, you should pay attention to its efficiency factor.
Pacific Biosciences of California Inc (PACB) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Devices Industry. The insider ownership of Pacific Biosciences of California Inc is 10.29%, while institutional ownership is 52.59%. The most recent insider transaction that took place on Aug 18 ’25, was worth 35,182. In this transaction an insider of this company sold 26,836 shares at a rate of $1.31, taking the stock ownership to the 1,920,035 shares. Before that another transaction happened on Aug 18 ’25, when Company’s Officer proposed sale 26,836 for $1.31, making the entire transaction worth $35,174.
Pacific Biosciences of California Inc (PACB) Recent Fiscal highlights
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.2 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -64.88% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.32% during the next five years compared to -23.55% drop over the previous five years of trading.
Pacific Biosciences of California Inc (NASDAQ: PACB) Trading Performance Indicators
Here are Pacific Biosciences of California Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.40. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.18, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.53 in one year’s time.
Technical Analysis of Pacific Biosciences of California Inc (PACB)
Compared to the last year’s volume of 9.29 million, its volume of 6.91 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 37.89%.
During the past 100 days, Pacific Biosciences of California Inc’s (PACB) raw stochastic average was set at 81.27%, which indicates a significant increase from 73.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.23 in the past 14 days, which was higher than the 0.13 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.90, while its 200-day Moving Average is $1.43. Nevertheless, the first resistance level for the watch stands at $2.48 in the near term. At $2.53, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.62. If the price goes on to break the first support level at $2.35, it is likely to go to the next support level at $2.26. Now, if the price goes above the second support level, the third support stands at $2.21.
Pacific Biosciences of California Inc (NASDAQ: PACB) Key Stats
With a market capitalization of 733.64 million, the company has a total of 301,907K Shares Outstanding. Currently, annual sales are 154,010 K while annual income is -309,850 K. The company’s previous quarter sales were 38,440 K while its latest quarter income was -38,000 K.
